[Federal Register: May 4, 1998 (Volume 63, Number 85)]
[Rules and Regulations]               
[Page 24420]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr04my98-8]


[[Page 24420]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
21 CFR Part 522

 
Implantation or Injectable Dosage Form New Animal Drugs; Propofol

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a new animal drug application 
(NADA) filed by Abbott Laboratories. The NADA provides for veterinary 
prescription use of propofol emulsion for intravenous injection in dogs 
as an anesthetic.

EFFECTIVE DATE: May 4, 1998.
FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center 
ForVeterinary Medicine (HFV-110), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-594-1612.

SUPPLEMENTARY INFORMATION: Abbott Laboratories, 1401 Sheridan Rd., 
North Chicago, IL 60064-4000, filed NADA 141-098 that provides for 
veterinary prescription use of PropoFlo<Register> (propofol) emulsion 
for intravenous injection in dogs for induction of anesthesia, 
maintenance of anesthesia, or induction of anesthesia where maintenance 
is provided by inhalation anesthetic. The NADA is approved as of March 
13, 1998, and the regulations are amended in 21 CFR 522.2005(b) to 
reflect the approval. The basis of approval is discussed in the freedom 
of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, 
between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii), this approval for nonfood-
producing animals qualifies for 3 years of marketing exclusivity 
beginning March 13, 1998, because the application contains substantial 
evidence of the effectiveness of the drug involved and studies of 
animal safety required for approval and conducted or sponsored by the 
applicant.
    The agency has determined under 21 CFR 25.33(d)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.

List of Subjects in 21 CFR Part 522

    Animal drugs.
    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is 
amended as follows:

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 522 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec. 522.2005  [Amended]

    2. Section 522.2005 Propofol injection is amended in paragraph (b) 
by removing ``No. 000061'' and adding in its place ``Nos. 000061 and 
000074''.

    Dated: April 22, 1998.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 98-11740 Filed 5-1-98; 8:45 am]
BILLING CODE 4160-01-F